2024-518039-12-00Active, not recruitingPhase 1
A Phase 1 Study to Determine the Safety, Tolerability and Pharmacokinetics of 177Lu-EVG321 in Patients with Small Cell Lung Cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Aug 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 7 Oct 2024
- Start date
- 27 May 2025
- Lead sponsor
- Evergreen Theragnostics Inc.
- Diseases
- Lung cancer
- EU CT number
- 2024-518039-12-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 20
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medizinische Universitaet Innsbruck | Innsbruck | Austria | Suspended |
| Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII | Bergamo | Italy | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.